Razelle Kurzrock

Research interests

Publications

• The coming decade in precision oncology: six riddles

  Nature reviews. Cancer · 2022 · https://doi.org/10.1038/s41568-022-00529-3

• Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00336-3

• Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2021-002990

• A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

  Clinical Cancer Research · 2020 · https://doi.org/10.1158/1078-0432.ccr-19-3356

• The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

  Cancer Cell · 2020 · https://doi.org/10.1016/j.ccell.2020.10.001

• Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-019-0424-4

• Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30904-5

• Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.75.3780

• International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

  Blood · 2018 · https://doi.org/10.1182/blood-2018-07-862334

• Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology

  Molecular Cancer Therapeutics · 2017 · https://doi.org/10.1158/1535-7163.mct-16-0436

• International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

  Blood · 2017 · https://doi.org/10.1182/blood-2016-10-746933

• Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

  Molecular Cancer Therapeutics · 2017 · https://doi.org/10.1158/1535-7163.mct-17-0386

• Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

  Clinical Cancer Research · 2016 · https://doi.org/10.1158/1078-0432.ccr-16-0318

• Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

  Oncotarget · 2016 · https://doi.org/10.18632/oncotarget.7110

• RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

  Clinical Cancer Research · 2016 · https://doi.org/10.1158/1078-0432.ccr-16-1679

• Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

  Molecular Cancer Therapeutics · 2016 · https://doi.org/10.1158/1535-7163.mct-15-0795

• FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

  Journal of Translational Medicine · 2016 · https://doi.org/10.1186/s12967-016-1075-6

• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

  Molecular Cancer Therapeutics · 2015 · https://doi.org/10.1158/1535-7163.mct-14-0983

• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.5997

• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)60398-5

• Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

  Clinical Cancer Research · 2008 · https://doi.org/10.1158/1078-0432.ccr-08-0024

• Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

  Blood · 2001 · https://doi.org/10.1182/blood.v97.1.256

• The Biology of Chronic Myeloid Leukemia

  New England Journal of Medicine · 1999 · https://doi.org/10.1056/nejm199907153410306

Current projects

No projects listed.